Dachaigh › Cancer Cealla Plasma
Sgrùdaidhean clionaigeach Cancer Cealla Plasma a’ fastadh anns na SA
Tha 24 sgrùdaidhean airson Cancer Cealla Plasma a’ fastadh phàirtichean aig làraichean air feadh nan Stàitean Aonaichte.
Bailtean leis na sgrùdaidhean as motha
- Boston, MA5 sgrùdaidhean
- Houston, TX5 sgrùdaidhean
- New York City, NY4 sgrùdaidhean
- Atlanta, GA4 sgrùdaidhean
- Durham, NC3 sgrùdaidhean
- Miami, FL3 sgrùdaidhean
Le stàit
- California3 sgrùdaidhean
- Florida4 sgrùdaidhean
- Georgia4 sgrùdaidhean
- Massachusetts5 sgrùdaidhean
- New Jersey4 sgrùdaidhean
- New York6 sgrùdaidhean
- North Carolina4 sgrùdaidhean
- Texas7 sgrùdaidhean
Sgrùdaidhean air an ùrachadh o chionn ghoirid
Teacsa sgrùdaidh oifigeil (Beurla)
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
A’ fastadhÌre 1/2
Aoisean 18 gu 80 · Gach gnè · Air ùrachadh 5 Dàmh 2026 · NCT06066359Rutgers University Study of the Genetics of Blood Cancers
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 18 gu 110 · Gach gnè · Air ùrachadh 1 Dàmh 2026 · NCT07714044Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2026 · NCT04879043Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 7 gu 80 · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT00106925MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
A’ fastadhÌre 3
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 24 Lùna 2026 · NCT06152575A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT05651932Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
A’ fastadhÌre 4
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Lùna 2026 · NCT07426484Delayed Toxicities Post-CAR-T
A’ fastadhSgrùdadh amharc
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Lùna 2026 · NCT07665307Pre-malignant States to Hematologic Malignancies in Firefighters
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
Aoisean 40 gu 49 · Gach gnè · Air ùrachadh 13 Iuch 2026 · NCT06870760Registry of Older Patients With Cancer
A’ fastadhSgrùdadh amharc
Aoisean 65 agus nas sine · Gach gnè · Air ùrachadh 29 Ògmh 2026 · NCT01137825A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
A’ fastadhÌre 1
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Ògmh 2026 · NCT05055063High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
A’ fastadhÌre 1
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 4 Ògmh 2026 · NCT06313502A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
A’ fastadhFàilte do shaor-thoilich fhallain
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 26 Cèit 2026 · NCT07052916Pilot Imaging Study of Leukemia
A’ fastadhÌre 1
Aoisean 4 gu 80 · Gach gnè · Air ùrachadh 23 Gibl 2026 · NCT03633955Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 15 Gibl 2026 · NCT05336383Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 20 Gearr 2026 · NCT05745285Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
A’ fastadh
Aoisean 21 agus nas sine · Gach gnè · Air ùrachadh 5 Gearr 2026 · NCT07390071Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 11 Dùbh 2025 · NCT06518551Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 3 Dùbh 2025 · NCT06947083Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
A’ fastadhÌre 1/2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Dàmh 2025 · NCT07075510Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
A’ fastadhSgrùdadh amharc
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 27 Dàmh 2025 · NCT01137643HEME Home Transfusion Program
A’ fastadh
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 17 Sult 2025 · NCT06487247Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 10 Gearr 2025 · NCT05597345A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
A’ fastadhÌre 1
Aoisean 18 gu 75 · Gach gnè · Air ùrachadh 2 Lùna 2024 · NCT06271252Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.